What CRISPR gene therapies are in clinical trials in 2026 and what do the results show?
Short answer
As of 2026, CRISPR-based therapies have entered pivotal clinical trials for sickle cell disease (Casgevy, FDA-approved December 2023), beta-thalassemia, certain cancers (CAR-T modifications), and hereditary angioedema. Casgevy (exagamglogene autotemcel) became the first CRISPR therapy to receive FDA approval, with clinical data showing 97% of sickle cell patients were free of vaso-occlusive crises for at least 12 months post-treatment.
Execution Steps
- 1Search for CRISPR clinical trials in LancetClaw.
- 2Review the latest published trial results with real PMIDs and sample sizes.
- 3Check which trials are Phase 1 vs Phase 2 vs Phase 3 — evidence strength varies dramatically.
- 4Compare efficacy endpoints across trials: cure rates, durability, safety profiles.
- 5Explore the ethical and access considerations flagged by LancetClaw.
Prompt Template
What are the latest clinical trial results for CRISPR-based therapies in [sickle cell/cancer/rare disease]?
Common Failure Points
- Confusing preclinical results with clinical trial data (many CRISPR results are still in animal models)
- Ignoring off-target effects — the main safety concern for all CRISPR therapies
- Assuming germline editing results apply to somatic therapies (they are fundamentally different)
- Not considering the cost and access barriers (gene therapies can cost $1-2 million per treatment)
FAQ
Composite User Feedback
Medical Student
"The answer pages helped me move from not understanding a paper to knowing which part I should read next."
Clinician
"These guides work because they answer the practical question first, then point me to the workflow I should use."
Medical Librarian
"The strongest pages are the ones that can stand alone as answers and still route people into the right LancetClaw skill."